ENTX: Borrow Market Whipsaws as Call Buyers Step In

Why this matters: Three distinct signals converged on ENTX this week. The borrow market swung from near-zero availability to relative ease in days. Simultaneously, options traders made the sharpest shift toward calls seen all year.

From Locked to Open: A Dramatic Borrow Reversal

The story starts in the lending pool. On September 17–18, availability on ENTX collapsed to 3.5–3.8% — one share still available for every 26 already borrowed. That is among the tightest borrow conditions the stock has recorded in a year.

Then the reversal came fast. By September 24, availability had rebounded to 60.8%. That is a 1,630% jump in one week. The pool loosened sharply, and short sellers moved quickly. Short interest jumped 49% in a single day, from roughly 892,000 shares to 1.33 million — a wave of new shorts entering as borrowing became practical again.

Cost to borrow remains elevated. It sits at 14.2%, up 30% over the past month. That level prices ENTX firmly in the hard-to-borrow tier, even after the availability recovery.

Call Buyers Flood the Options Market

While the borrow market was whipsawing, the options market told a different story. The put-call ratio dropped to 1.07 on September 24. The 20-day average was 5.23. That is a z-score of –2.10 — the lowest PCR reading in 52 weeks.

For most of August and early September, ENTX options were overwhelmingly skewed toward puts. PCR readings of 6–9 were routine. The flip to ~1.07 represents an aggressive rotation into calls. Something changed in how options traders are positioning on this name.

Analyst Coverage Builds a Bull Case

The options shift arrives just days after two fresh initiations. Cantor Fitzgerald initiated coverage with an Overweight rating on September 22. Leerink Partners initiated Outperform with a $9.00 target on September 18. The consensus now sits at Buy, with a mean price target of $9.33 — more than three times the September 24 close of $2.80.

The bull case rests on EB613, Entera Bio's Phase 3 osteoporosis candidate, and FDA alignment on its primary endpoint. Bears point to competition from existing treatments and clinical-stage financial risk.

BVF Partners L.P. filed a Schedule 13D in August, disclosing a 9.99% activist stake — as last disclosed, per regulatory timing conventions. Several other institutions disclosed large new positions in the same August filing window. The register became notably more concentrated in a short period.

Data Summary

• SI % of Free Float: 2.9% (up 49% in one day, up 47% over one week)
• Availability: 60.8% as of Sep 24, rebounded from 3.5% low on Sep 17
• Cost to Borrow: 14.2%, up ~30% over one month
• Put-Call Ratio: 1.07 vs. 20-day average of 5.23 (52-week low)
• Analyst consensus: Buy | Mean target $9.33 | Stock at $2.80
• Next earnings: November 6, 2026
• BVF Partners 13D stake: 9.99% (filed August 4, 2026 — as last disclosed)